Sheaff Brock Investment Advisors, LLC Halozyme Therapeutics, Inc. Transaction History
Sheaff Brock Investment Advisors, LLC
- $1.13 Billion
- Q3 2024
A detailed history of Sheaff Brock Investment Advisors, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Sheaff Brock Investment Advisors, LLC holds 7,118 shares of HALO stock, worth $396,970. This represents 0.04% of its overall portfolio holdings.
Number of Shares
7,118
Previous 6,611
7.67%
Holding current value
$396,970
Previous $346,000
17.63%
% of portfolio
0.04%
Previous 0.03%
Shares
4 transactions
Others Institutions Holding HALO
# of Institutions
539Shares Held
126MCall Options Held
294KPut Options Held
180K-
Black Rock Inc. New York, NY17.6MShares$983 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$719 Million0.01% of portfolio
-
State Street Corp Boston, MA6.63MShares$370 Million0.02% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.06MShares$227 Million5.07% of portfolio
-
Alliancebernstein L.P. New York, NY3.41MShares$190 Million0.07% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.77B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...